Form 4: Stryker Corp Director Maceda Receives Stock Grant with Deferred Settlement

Director Emmanuel Perez Maceda received a grant of Restricted Stock Units (RSUs) from Stryker Corp, with settlement deferred until May 1, 2030.

Summary

• On May 8, 2025, Emmanuel Perez Maceda, a director of Stryker Corp, was granted 560 Restricted Stock Units (RSUs).
• The RSUs will vest on the earlier of the date of the 2026 Annual Meeting of Shareholders or May 8, 2026.
• Maceda has elected to defer receipt of the Stryker Common Stock shares issuable upon settlement of the RSUs until May 1, 2030.
• Each RSU represents a contingent right to receive one share of Stryker Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The deferred settlement could be viewed positively as a sign of long-term commitment.

Positives

• The grant of RSUs aligns the director's interests with the long-term performance of Stryker Corp.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the RSU grant suggests an expectation of continued success.

Industry Context

Equity compensation is a common practice for aligning the interests of company directors with those of shareholders in the healthcare industry.

Comparison to Industry Standards

• RSU grants are a standard form of executive compensation across the S&P 500, including companies like Johnson & Johnson and Medtronic.
• Deferred settlement of equity awards is less common but can be used for tax planning or to further incentivize long-term commitment.

Stakeholder Impact

• The RSU grant aligns the director's interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

Stryker Corp, RSU, Restricted Stock Units, Director, Maceda, Equity Compensation, Form 4